James B. Wetmore, MD, MS,^{1,2} Jiannong Liu, PhD,¹ Kimberly A. Lowe, PhD, MHS,³ Areef Ishani, MD,MS,^{1,2,4} Thy P. Do, PhD,³ Brian D. Bradbury, DSc,³ Geoffrey A. Block, MD,⁵ Allan J. Collins, MD^{1,2}

¹Chronic Disease Research Group, Minneapolis Medical Research Foundation and ²Division of Nephrology, Hennepin County Medical Center, Minneapolis, MN; ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA; 4Minneapolis VA Health Care System, Minneapolis, MN; 5Denver Nephrology Clinical Research Division, Denver, CO



CDRG Characteristics Associated with Parathyroidectomy in Medicare Hemodialysis Patients

Introduction

- Secondary hyperparathyroidism (SHPT) occurs in more than half of patients on hemodialysis (HD)1
- KDIGO guidelines state that dialysis patients with severe SHPT who fail to respond to medical therapy should undergo a parathyroidectomy (PTX)
- While there is a paucity of data describing the clinical consequences in the year following PTX, we have recently described such outcomes in a large cohort of Medicare dialysis patients²
- However, differences between patients who do and do not undergo PTX have never been rigorously examined
- Our objective was to determine factors associated with PTX

- 1 Danese MD et al. Arbor Research Collaborative for Health: Dialysis Outcomes Practice Patterns Study (DOPPS) Practice Monitor, 2013
- 2 Ishani A et al, NKF poster # 100, 2014 3 Liu J et al, Kidney Int 77:141, 2010

Methods


- United States Renal Data System (USRDS) data was used to create a cohort of prevalent adult HD patients from 2007-09
- Patients were required to have Medicare as primary payer for both Parts A and Part B, and to have been receiving HD >1 year
- inpatient claims using ICD-9-CM (International Classification of Diseases. Ninth Revision, Clinical Modification) procedure codes 06.8x and 06.95
- January 1 for the non-PTX patients

· Odds ratios (ORs) for PTX were calculated using logistic regression


Results

- PTX was identified from Medicare
- In each year, an index date was defined as the PTX date for PTX patients, and as
- Comorbid conditions, assessed in the year prior to index date, were defined by previously established USRDS methods3
- · Characteristics of the patients who did and did not undergo PTX were assessed. Models were adjusted for demographics cause of end stage renal disease (ESRD) body mass index, dialysis vintage, comorbidities, and ESRD Network

Characteristics of







Discussion As shown in Figure 1, after adjustment, vounger age

- In this large study, we have identified several factors associated with use of PTX
- Patients receiving a PTX have factors that are traditionally associated with more severe SHPT, including black race, younger age, and longer dialysis vintage
- Greater BMI and presence of cardiovascular disease is also associated with PTX
- Geography is also associated with PTX, with a nearly 2-fold variation in OR for PTX among the least- and most-frequently performing networks
- Our study has important limitations. For example, we lacked information on laboratory values and medication use, both of which would be expected to influence likelihood of PTX. Other patient-level characteristics which likely influenced bedside decisions to undertake PTX were also unobservable to us.

significantly associated with comorbidity, and history of a

There was a 1.95-fold difference in OR for PTX between the most- and least-frequently PTXperforming regions; 7 regions had an OR > 1.5.

a decreased OR for PTX.

(19-44 yrs, versus 45-64),

female sex, black (versus

atherosclerotic heart or

other cardiac disease were

Age ≥ 65, diabetes as the

significantly associated with

vintage ≥ 3 yrs, and

increased OR for PTX.

cause of ESRD or as a

stroke or TIA were

white) race, BMI ≥ 30 kg/m²,

914 South 8th street | Suite S-2-100 Minneapolis MN, 55404 | 612,873,6200

Study funded by Amgen, Inc.